What Is Ipamorelin?
Ipamorelin (GHRP) is classified as a ghrp peptide. Selective GH secretagogue that mimics ghrelin at the GHS receptor. Does not significantly raise cortisol or prolactin, making it one of the most selective GH-releasing peptides.
It is extensively evaluated in laboratory and clinical settings for its potential to drive gh release, muscle growth, recovery without cortisol spike. Researchers target Ipamorelin for its ability to interact with specific cellular and molecular pathways, making it a compound of significant interest across multiple therapeutic domains.
One of the safest GH peptides. Side effects may include transient headache, flushing. Not FDA-approved.
How Does Ipamorelin Work?
Selective GH secretagogue that mimics ghrelin at the GHS receptor. Does not significantly raise cortisol or prolactin, making it one of the most selective GH-releasing peptides.
At the molecular level, Ipamorelin operates through pathways characteristic of the GHRP class. By interacting with target receptors and downstream signaling cascades, the compound initiates biological responses associated with gh release, muscle growth, recovery without cortisol spike.
Expected Research Timeline
Weeks 2–4
Improved recovery and energy; early body composition shifts
Months 2–3
Visible lean mass gains; fat loss (especially combined with CJC-1295)
Long-Term
Sustained IGF-1 support; preserved muscle during caloric deficit
What Does the Research Say?
The following are key findings from peer-reviewed studies on Ipamorelin, indexed on PubMed and equivalent databases:
[1]Ipamorelin selective GH release original characterization
Raun et al. (Eur. J. Endocrinol.): First characterization showing Ipamorelin releases GH potently and selectively without raising ACTH, cortisol, prolactin, FSH, LH, or TSH in swine.
Evidence: moderate[2]Ipamorelin PK/PD modeling in healthy human volunteers
Dose-escalation study in healthy humans demonstrates Ipamorelin induces single-episode GH release with peak at ~0.67 hours and terminal half-life of 2 hours.
Evidence: moderate[3]Ipamorelin and longitudinal bone growth in rats
Svensson et al. show Ipamorelin induces dose-dependent longitudinal bone growth and counters glucocorticoid-induced decreases in bone formation and muscle strength.
Evidence: preclinical[4]Ipamorelin accelerates postoperative GI recovery
Preclinical evidence demonstrates Ipamorelin alleviates delayed gastric emptying and post-surgical ileus, suggesting applications beyond hormone optimization.
Evidence: preclinicalSafety & Side Effects
One of the safest GH peptides. Side effects may include transient headache, flushing. Not FDA-approved.
| Side Effect | Incidence | Severity |
|---|---|---|
| Temporary hunger | ~12% of users | mild |
| Headache | ~5% of users | mild |
| Water retention | ~8% of users | mild |
| Flushing / warmth | ~4% of users | mild |
FDA Status: Not Approved for Human Therapeutic Use
Ipamorelin is not currently FDA-approved for human use. It is available for research purposes only. Always consult a licensed healthcare provider.
How Is Ipamorelin Used?
Route
SubQ
Dose Range
300–300 mcg
Frequency
7x/wk
Cycle
8–8 wk
Timing: Pre-bed, morning fasted, or post-workout
Notes: Most commonly dosed at 200-300mcg per injection. Best taken on empty stomach 2+ hrs after eating.
All dosing information reflects parameters reported in published research literature and is not intended as clinical guidance. Usage of any peptide should be supervised by a qualified healthcare professional.
Ipamorelin vs. Related Compounds
Where to Source Ipamorelin for Research
Purchasing ultra-high purity, laboratory-grade peptides is critical for verifiable research. We only recommend vendors providing independent, third-party HPLC Certificates of Analysis (COA).
Disclosure: PeptiDex may earn a commission from purchases. This does not affect our recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Frequently Asked Questions
What is Ipamorelin?
Ipamorelin is a ghrp peptide. Selective GH secretagogue that mimics ghrelin at the GHS receptor. Does not significantly raise cortisol or prolactin, making it one of the most selective GH-releasing peptides.
What are the primary research benefits of Ipamorelin?
Published research identifies primary mechanisms targeting: GH release, muscle growth, recovery without cortisol spike. These findings come from 4+ peer-reviewed studies indexed in our database.
What is the half-life of Ipamorelin?
In published pharmacokinetic data, Ipamorelin demonstrates a half-life of approximately 2 hours.
Is Ipamorelin FDA approved?
Ipamorelin is not currently FDA-approved for human therapeutic use. It is classified as a research compound and is studied under investigational protocols. Always consult a healthcare provider.
What are common side effects of Ipamorelin?
Reported side effects in published literature include Temporary hunger (~12% of users), Headache (~5% of users), Water retention (~8% of users), Flushing / warmth (~4% of users). Most are classified as mild in severity.
How is Ipamorelin administered?
In research settings, Ipamorelin is typically administered via SubQ. Most commonly dosed at 200-300mcg per injection. Best taken on empty stomach 2+ hrs after eating.
Sources
- Ipamorelin selective GH release original characterization. View on PubMed
- Ipamorelin PK/PD modeling in healthy human volunteers. View on PubMed
- Ipamorelin and longitudinal bone growth in rats. View on PubMed
- Ipamorelin accelerates postoperative GI recovery. View on PubMed